Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Conditions:   Grade 2 Glioma;   Residual Glioma;   Recurrent Glioma Interventions:   Drug: AG-881;   Drug: Matching Placebo Sponsor:   Agios Pharmaceuticals, Inc. Not yet recruiting

Source: ClinicalTrials.gov - November 15, 2019 Category: Research Source Type: clinical trials